Aptevo Reports Q1 Net Loss of $6.79M, EPS $(6.41) Amidst Going Concern Warning
summarizeSummary
Aptevo Therapeutics reported a Q1 2026 net loss of $6.79 million, or $(6.41) per share, indicating a wider loss compared to the prior year. This financial update is critical given the company's previous disclosure of substantial doubt about its ability to continue as a going concern in its last 10-K filing. While the company recently announced positive Phase 1b clinical results for mipletamig and secured a new $60 million equity line of credit, providing $14.5 million in cash, the ongoing operational losses highlight the significant cash burn. Traders will need to assess these specific loss figures to understand the company's financial health and burn rate, despite the recent financing, as it continues to advance its clinical pipeline.
At the time of this announcement, APVO was trading at $4.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6M. The 52-week trading range was $3.80 to $258.01. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.